The FDA no longer plans to implement a guidance outlining a new naming protocol for biologics and biosimilars. The guidance would have required hospitals to spend hundreds of millions to overhaul their EHR systems.
FDA scraps biosimilar guidance, saving hospitals EHR headaches
